By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Castle Biosciences today announced it has licensed the BAP1 gene from Washington University in St. Louis for detecting metastasis in patients with melanoma.

The Friendswood, Texas-based firm has begun validation studies for use of the technology in both uveal melanoma, or ocular melanoma, and cutaneous melanoma and plans to incorporate the gene into its DecisionDx-UM assay. It also has an option for use of the gene for other cancers.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.